Indications for BRYHALI:
≥18yrs: apply a thin layer to affected areas once daily; max 50g/week. Treatment lasting >8 weeks: not recommended. Discontinue when control is achieved. Do not occlude.
<18yrs: not established.
Not for oral, ophthalmic, or intravaginal use. Avoid use on the face, groin, or axillae. Risk of HPA axis suppression with high-potency corticosteroids, prolonged use, application to large surface areas, occlusive use, altered skin barrier, concomitant multiple corticosteroid-containing products, liver failure, young age; discontinue gradually, reduce dose, or substitute with less potent corticosteroid if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Treat infection if present; discontinue until resolved. Reevaluate periodically. Discontinue if allergic contact dermatitis occurs. Pregnancy. Nursing mothers: avoid nipple/areola area due to infant exposure.
Upper respiratory tract infection, application site dermatitis, hyperglycemia; local adverse reactions (eg, atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, miliaria), Cushing’s syndrome, glucosuria, HPA axis suppression (esp. in children).
Generic Drug Availability: